目的：探讨阿德福韦酯联合双环醇治疗中老年人慢性乙型肝炎临床疗效和安全性。方法：96名中老年慢乙肝患者被随机分为两组,分别是治疗组和对照组。在基本的常规保肝治疗下,治疗组给予患者阿德福韦酯(10mg/ d)和双环醇 (25 mg,tid)。口服, 那些对照组只口服阿德福韦酯(10mg/ d)。两组的疗程均为24周。比较实验前后血清ALT、AST,病毒学参数的改变。结果：治疗之前和24周治疗后的比较,ALT水平分别在两组的值是：治疗组为(208.44 + / - 94.22)和(34.47 + / - 12.79)U / L,对照组为(205.73 + / - 96.48)和(44.20 + / - 21.96)U / L。(P < 0.01)。24周治疗结束后,ALT正常化比值在两组中,分别是76.6%和54.5%, AST的正常化比值分别是76.6%和54.5%(两组间差异P < 0.05); HBV DNA在治疗组和对照组降低(3.1 + / - 1.40)lg IU /毫升和(2.98±1.17)lg IU /毫升,分别为(P > 0.05组之间的差异)。不良事件的发生率在两组之间没有统计学意义。结论：因此在治疗中老年人慢性乙型肝炎时阿德福韦酯联合双环醇治疗是有效的和安全的。


The clinical efficacy and safety of adefovir in combination with bicyclol for the treatment of senior patients with chronic hepatitis B

OBJECTIVE To investigate the clinical efficacy and safety of adefovir(ADV) in combination with bicyclol for the treatment of chronic hepatitis B (CHB) in seniors. METHODS 96 senior patients with CHB were randomly divided into two groups, the treatment group and the control group. On the basis of routine liver protective treatment, patients in the treatment group received ADV (10 mg/d) and bicyclol tablets (25 mg, tid.) orally, and those in the control group were orally administrated ADV tablets (10 mg/d) only. The treatment course for both groups was 24 weeks. Serum ALT, AST, and alterations of virological parameters were observed before and after the treatment. RESULTS Before and at the end of the 24 weeks treatment, ALT level for the treatment group was (208.44 +/- 94.22) and (34.47 +/- 12.79) U/L, and those for the control group was (205.73 +/- 96.48) and (44.20 +/- 21.96) U/L, respectively (difference between groups P < 0.01). At the end of the 24 weeks treatment, ALT normalization rates for the treatment group and the control group were 76.6% and 54.5%, respectively, and AST normalization rates for them were 76.6% and 54.5%, respectively (both differences between groups P < 0.05); HBV DNA loads for the treatment group and the control group were decreased by (3.1 +/- 1.40) lgIU/ml and (2.98 +/- 1.17) lgIU/ ml, respectively (difference between groups P > 0.05). The incidence rates of adverse events between two groups were not statistically significant. CONCLUSION It suggested that the treatment of ADV in combination with bicyclol for senior patients with CHB is effective and safe.

点击下载 观察阿德福韦酯联合双环醇治疗中老年人慢性乙型肝炎的临床疗效和安全性